查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301123

CAR T 细胞治疗市场规模、份额和趋势分析报告：按产品、按适应症、最终用途、按地区、细分市场趋势，2023-2030年

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

CAR T 细胞治疗市场增长和趋势

根据Grand View Research, Inc.最新报告，预计2023年至2030年全球CAR T细胞治疗市场规模将以23.32%的复合年增长率增长，2030年达到159.7亿美元。

CAR T 细胞疗法通过利用患者的免疫系统杀死癌细胞，代表了淋巴瘤、多发性骨髓瘤和白血病等血癌治疗的范式转变。新兴国家多发性骨髓瘤等癌症患病率的上升正在推动市场发展。产品批准和重点药物管道形式的强有力的监管支持也进一步增强了该行业。例如，根据美国国家医学图书馆 2023 年 4 月的公告，世界各地正在开展大约 310 项与 CAR T 细胞相关的研究，涉及早期 I 期、I 期和 II 期。

多家公司已经建立了战略合作伙伴关係，并且随着地域扩张，面临着覆盖世界各地治疗的压力。因此，公司正在采取策略，扩大在没有潜在治疗方法或无法获得血液癌症治疗的国家的地理足迹。例如，2022年8月31日，Gilead旗下医疗公司Kite宣布在沙特阿拉伯、巴西和新加坡扩大其CAR T细胞疗法。该公司已报告新加坡有超过 1000 例非霍奇金淋巴瘤 (NHL) 病例，沙特阿拉伯已诊断出约 1700 例。同样，巴西每年发现约 12,000 例非霍奇金淋巴瘤病例。

COVID-19 大流行使得对患者进行 CAR T 细胞治疗变得困难，特别是在大流行早期，当时许多医院和诊所都挤满了 COVID-19 患者。许多医院不得不推迟或停止选择性治疗，包括 CAR T 细胞治疗，为 COVID-19 患者保留资源。此外，CAR T细胞疗法还有显着的副作用，例如细胞因子释放综合征（CRS），它会导致发烧、低血压和类似COVID-19症状的器官损伤，从而带来治疗问题。这是正确的。

此外，发展中国家兴起的医院和癌症治疗中心也越来越多地引入CAR T细胞。由于具有成本效益和时间效益的癌症治疗促进了市场的整体增长，这些中心正在蓬勃发展。例如，2022年8月，墨西哥癌症治疗中心免疫治疗研究所推出了一项业务，为美国和加拿大的患者提供CAR T细胞。同样，在以色列，整个过程都是在内部完成的，处理可以在大约10天内完成，从而节省大量成本。

新兴国家熟练专业人员的短缺以及与治疗相关的高昂费用仍然是市场增长的挑战。然而，随着人们对技术先进的 CAR T 细胞疗法的认识不断提高并获得越来越多的批准，预计将缓解这些挑战并促进预测期内的市场增长。据美国癌症治疗中心称，截至 2023 年，美国 FDA 已批准六种 CAR T 细胞疗法用于治疗血癌。

CAR T 细胞治疗市场报告亮点

  • 从产品来看，Yescarta (axicabtagene ciloleucel) 细分市场在 2022 年以 43.76% 的份额占据主导地位。Yescarta 的高吸收率归因于其强大的性能和改善的复发性 B 细胞大细胞淋巴瘤成年患者的生存率。
  • 从2022年的疾病指征来看，淋巴瘤所占比例最大，为57.15%。该领域的高市场渗透率是由于该疾病在全球范围内的高患病率。此外，市场参与者对去除 CD-19 抗原的强烈产品关注也推动了增长。
  • 按最终用途划分，医院业务由于其强大的财务和运营资源，到 2022 年将占据 56.26% 的多数份额。此外，医院实验室由于加快了这一过程而获得了很高的份额。
  • 2022 年，北美以 66.70% 的份额占据市场主导地位。所占比例之大可能是由于患者人数众多，并且由于快速批准和强大的医疗覆盖范围而总体获得常见和復杂的医疗保健。

目录

第一章 调查方法和范围

  • 市场细分和范围
    • 市场定义
  • 信息采购
    • 市场形成和数据可视化
    • 验证和发布数据
  • 调查假设
  • 调查方法
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查详情
  • 信息或数据分析
    • 数据分析模型
  • 市场形成和验证
  • 型号详情
    • 产品流向分析
  • 二级信息列表
  • 全球市场：CAGR计算的目的

第二章执行摘要

  • 市场快照
  • 段快照
  • 竞争格局的快照

3. 市场变量、趋势和范围

  • 市场谱系展望
    • 母公司市场展望
    • 相关/补充市场展望
  • 市场趋势和前景
  • 市场动态
    • 市场驱动力分析
    • 市场约束因素分析
  • 营商环境分析
    • SWOT 分析：按因素（政治/法律、经济/技术）
    • 波特五力分析
    • COVID-19 的影响分析

第四章 CAR T 细胞治疗市场：产品估算和趋势分析

  • 2022 年和 2030 年产品变化分析和市场份额
  • 按产品
  • Abecma（idecabtagene vicleucel）
    • 2018-2030 年全球 Abekuma（Idekbutagen 车辆）市场（百万美元）
  • Breyanzi (lisocabtagene maraleucel)
    • 全球 Brayange（Lithocabtagen Malaleusel）市场，2018-2030 年（百万美元）
  • Carvykti（ciltacabtagene autoleucel）
    • 全球 Curvixty (Siltaka Butagen Autoleucel) 市场，2018-2030 年（百万美元）
  • Kymriah（tisagenlecleucel）
    • 全球 Kymriah (Tisagen Lukrusel) 市场，2018-2030 年（百万美元）
  • Tecartus（brexucabtagene autoleucel）
    • 全球 Tecartas (Brexcabutagen Autoleucel) 市场，2018-2030 年（百万美元）
  • Yescarta（axicabtagene ciloleucel）
    • 全球市场 Yescarta (Axica Butagensiloleucer)，2018-2030（百万美元）
  • 其他
    • 世界其他地区市场，2018-2030（百万美元）

第五章 CAR T细胞治疗市场：适应症估计和趋势分析

  • 2022 年和 2030 年指示变化分析和市场份额
  • 按疾病
  • 白血病
    • 全球白血病市场，2018-2030（百万美元）
  • 淋巴瘤
    • 全球淋巴瘤市场，2018-2030（百万美元）
  • 多发性骨髓瘤
    • 全球多发性骨髓瘤市场，2018-2030（百万美元）

第六章最终用途业务分析

  • 2022 年和 2030 年的最终用途变化分析和市场份额
  • 按最终用途
  • 医院
    • 医院市场，2018-2030（百万美元）
  • 癌症治疗中心
    • 癌症治疗市场，2018-2030（百万美元）

第七章区域业务分析

  • CAR T 细胞治疗市场：区域展望
  • 北美
    • 北美 CAR T 细胞疗法市场估计和预测，2018-2030 年（百万美元）
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲 CAR T 细胞疗法市场估计和预测（百万美元）
    • 德国
    • 英国
  • 亚太地区
    • 2018-2030 年亚太地区 CAR T 细胞治疗市场估计和预测（百万美元）
    • 日本
    • 中国
  • 世界其他地区
    • 2018-2030 年世界其他地区 CAR T 细胞疗法市场估计和预测（百万美元）

第8章 竞争格局

  • 公司分类
  • 战略规划
  • 公司简介/名单
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences Inc
    • Bluebird Bio Inc
    • Johnson & Johnson Services Inc
    • Merck & Co.
    • Sorrento Therapeutics Inc
    • Sangamo Therapeutics
    • GSK Plc.
    • JW Therapeutics（Shanghai）Co., Ltd.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Growth & Trends

The global CAR T-cell therapy market size is expected to reach USD 15.97 billion by 2030, expanding at 23.32% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights

  • By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 43.76% in 2022. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
  • Lymphoma accounted for the largest share of 57.15% in the disease indication segment in 2022. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
  • By end-use, the hospital segment captured a majority share of 56.26% in 2022 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
  • North America has shown a dominant position in the market with a 66.70% share in 2022. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Market definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Disease indication segment
      • 1.1.1.3. End-use segment
  • 1.2. Information Procurement
    • 1.2.1. Market formulation & data visualization
    • 1.2.2. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Research Methodology
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
      • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. Global Market: CAGR CalculationObjectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Growing cases of Cancer Malignancies across population
      • 3.3.1.2. Targeted treatment approach mitigates relapsed or refracted blood cancer cases.
      • 3.3.1.3. Robust product pipeline with regulatory approvals across geographies.
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High drug cost impedes the market growth
      • 3.3.2.2. Side-effects of CAR T-cell therapy
      • 3.3.2.3. Complex Manufacturing and Supply Chain
  • 3.4. Business Environment Analysis
    • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Movement Analysis & Market Share, 2022 & 2030
  • 4.2. CAR T-cell Therapy Market Estimates & Forecast, By Product (USD Million)
  • 4.3. Abecma (idecabtagene vicleucel)
    • 4.3.1. Global Abecma (idecabtagene vicleucel) Market, 2018 - 2030 (USD Million)
  • 4.4. Breyanzi (lisocabtagene maraleucel)
    • 4.4.1. Global Breyanzi (lisocabtagene maraleucel) Market, 2018 - 2030 (USD Million)
  • 4.5. Carvykti (ciltacabtagene autoleucel)
    • 4.5.1. Global Carvykti (ciltacabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.6. Kymriah (tisagenlecleucel)
    • 4.6.1. Global Kymriah (tisagenlecleucel) Market, 2018 - 2030 (USD Million)
  • 4.7. Tecartus (brexucabtagene autoleucel)
    • 4.7.1. Global Tecartus (brexucabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.8. Yescarta (axicabtagene ciloleucel)
    • 4.8.1. Global Yescarta (axicabtagene ciloleucel) Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

  • 5.1. Disease Indication Movement Analysis & Market Share, 2022& 2030
  • 5.2. CAR T-cell Therapy Market Estimates & Forecast, By Disease Indication (USD Million)
  • 5.3. Leukemia
    • 5.3.1. Global Leukemia Market, 2018 - 2030 (USD Million)
  • 5.4. Lymphoma
    • 5.4.1. Global Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.5. Multiple Myeloma
    • 5.5.1. Global Multiple Myeloma Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Movement Analysis & Market Share, 2022& 2030
  • 6.2. CAR T-cell Therapy Market Estimates & Forecast, By End-use (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4. Cancer Treatment Centers
    • 6.4.1. Cancer Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. CAR T-cell Therapy Market: Region Outlook
  • 7.2. North America
    • 7.2.1. North America CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.2. The U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Disease Prevalence
      • 7.2.2.5. U.S. CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Disease Prevalence
      • 7.2.3.5. Canada CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Disease Prevalence
      • 7.3.2.5. Germany CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Disease Prevalence
      • 7.3.3.5. UK CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Disease Prevalence
      • 7.4.2.5. Japan CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Disease Prevalence
      • 7.4.3.5. China CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Rest of World
    • 7.5.1. Rest of World CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Bristol-Myers Squibb Company
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Novartis AG
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
      • 8.3.2.5. Overview
      • 8.3.2.6. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.7. Product Benchmarking
      • 8.3.2.8. Strategic Initiatives
    • 8.3.3. Gilead Sciences Inc
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bluebird Bio Inc
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Johnson & Johnson Services Inc
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Merck & Co.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sorrento Therapeutics Inc
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Sangamo Therapeutics
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. GSK Plc.
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 3 Global CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 4 Global CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Global CAR T-cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 9 North America CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15 Canada CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 17 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 18 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 19 Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 22 Germany CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 24 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 25 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Rest of Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Rest of Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 29 Rest of Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 35 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 36 China CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 39 Japan CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Rest of Asia-Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 41 Rest of Asia-Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 42 Rest of Asia-Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 44 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 45 Rest of World CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 CAR T-cell Therapy sequencing market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global CAR T-cell therapy: product movement analysis
  • Fig. 16 Global CAR T-cell therapy, for Abecma, 2018 - 2030 (USD million)
  • Fig. 17 Global CAR T-cell therapy, for Breyanzi, 2018 - 2030 (USD million)
  • Fig. 18 Global CAR T-cell therapy, for Carvykti, 2018 - 2030 (USD million)
  • Fig. 19 Global CAR T-cell therapy, for Kymriah, 2018 - 2030 (USD million)
  • Fig. 20 Global CAR T-cell therapy, for Tecartus, 2018 - 2030 (USD million)
  • Fig. 21 Global CAR T-cell therapy, for Yescarta, 2018 - 2030 (USD million)
  • Fig. 22 Global CAR T-cell therapy: disease indication movement analysis
  • Fig. 23 Global CAR T-cell therapy, for leukaemia, 2018 - 2030 (USD million)
  • Fig. 24 Global CAR T-cell therapy, for lymphoma, 2018 - 2030 (USD million)
  • Fig. 25 Global CAR T-cell therapy, for multiple myeloma, 2018 - 2030 (USD million)
  • Fig. 26 Global CAR T-cell therapy: end-use movement analysis
  • Fig. 27 Global CAR T-cell therapy, for hospitals, 2018 - 2030 (USD million)
  • Fig. 28 Global CAR T-cell therapy, for cancer treatment centers, 2018 - 2030 (USD million)
  • Fig. 29 Regional marketplace: key takeaways
  • Fig. 30 Regional outlook, 2022 & 2030
  • Fig. 31 Global CAR T-cell therapy: region movement analysis
  • Fig. 32 North America CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 33 U.S. CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 34 Canada CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 35 Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 36 Germany CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 37 UK CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 38 Rest of Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 40 Japan CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 41 China CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 42 Rest of Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 43 Rest of World CAR T-cell therapy, 2018 - 2030 (USD million)